SCHEMBL20746476

SCHEMBL20746476

[CH2]C(Cl)c1ccc2ccccc2n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NCF1 P14598 3/20 0.43
CYP1A2 P05177 2/20 0.43
NOS2 P35228 1/20 0.43
BACE1 P56817 1/20 0.43
CA12 O43570 1/20 0.43
CA9 Q16790 1/20 0.43
ALDH1A1 P00352 3/20 0.42
HSD17B10 Q99714 1/20 0.42
S1PR3 Q99500 1/20 0.42
GLA P06280 1/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
ACHE P22303 1/20 0.39
CNR2 P34972 1/20 0.39
MGAM O43451 1/20 0.38
RAB9A P51151 7/20 0.37
NPC1 O15118 6/20 0.37
AR P10275 2/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3294485 0.83 NCF1 (0.46) NCF1CYP1A2NOS2BACE1CA12
SCHEMBL4064465 0.79 ALDH1A1 (0.50) NCF1CYP1A2NOS2BACE1CA12
SCHEMBL7461862 0.79 ALDH1A1 (0.50) NCF1CYP1A2NOS2BACE1CA12
SCHEMBL4848414 0.79 CYP1A2 (0.48) NCF1CYP1A2NOS2BACE1CA12
SCHEMBL3089963 0.79 CYP1A2 (0.48) NCF1CYP1A2NOS2BACE1CA12
SCHEMBL9009627 0.78 NCF1 (0.50) NCF1CYP1A2NOS2BACE1CA12
SCHEMBL21580901 0.75 NCF1 (0.43) NCF1CYP1A2NOS2BACE1CA12
SCHEMBL10518600 0.75 ALDH1A1 (0.46) NCF1CYP1A2NOS2BACE1CA12
SCHEMBL827081 0.74 CYP1A2 (0.52) NCF1CYP1A2NOS2BACE1CA12
SCHEMBL10020390 0.74 ALDH1A1 (0.53) NCF1CYP1A2NOS2BACE1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11795162-B2 Modulators of the estrogen-related receptor SAINT LOUIS UNIVERSITY (US) 2023-10-24 US disclosed
US-20200247792-A1 ERR INVERSE AGONISTS SAINT LOUIS UNIVERSITY (US) 2020-08-06 US disclosed
WO-2019036562-A1 ERR INVERSE AGONISTS SAINT LOUIS UNIVERSITY (US) 2019-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200247792-A1 ERR INVERSE AGONISTS ESRRA, ESRRB, ESR2 NCF1 3690/4885CYP1A2 434/4885NOS2 3376/4885
US-11795162-B2 Modulators of the estrogen-related receptor ESR2, GPER1, ESRRG NCF1 3385/4885CYP1A2 775/4885NOS2 4019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.